The lightest scalar glueball

Recently performed investigations of meson spectra allow us to determine the resonance structure for the waves $IJ^{PC}=00^{++}$, $10^{++}$, $02^{++}$, $12^{++}$ = $IJ^P= 1/2 0^+$ in the mass region up to 1900 MeV, thus establishing the meson multiplets $1^3P_0q\bar q$ and $2^3P_0q\bar q$. Experimental data demonstrate that there are five scalar/isoscalar states in this mass region. Four of them are $q\bar q$ states, that is, members of the $1^3P_0q\bar q$ and $2^3P_0q\bar q$ nonets, while the fifth state is an extra one not accomodated by $q \bar q$ systematics; it has the properties of the lightest scalar glueball. Analysis of the $00^{++}$-wave performed within the framework of the dispersion relation technique allows us to reconstruct the mixing of a pure gluonium with neighbouring scalar $q \bar q$ states belonging to $1^3P_0q\bar q$ and $2^3P_0q\bar q$ nonets: three scalar mesons share the gluonium state between each other -- those are two comparatively narrow resonances $f_0(1300)$ and $f_0(1500)$ and a broad resonance $f_0(1530^{+90}_{-250})$. The broad state is a descendant of the gluonium, keeping about 40-50% of its component.Comment: 48 pages, LaTeX, 25 PostScript figures, epsfig.sty. Submitted to Russian Journal Uspekhi Fiz. Nauk (Phys-Uspekhi

Centrality evolution of the charged-particle pseudorapidity density over a broad pseudorapidity range in Pb-Pb collisions at root s(NN)=2.76TeV

Peer reviewe

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Supported by Janssen Research & Development, LLC.PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it has not yet been evaluated for ibrutinib + venetoclax treatment.METHODSUndetectable MRD (uMRD) was assessed by next-generation sequencing at <1 CLL cell per 10,000 (<10-4) and <1 CLL cell per 100,000 (<10-5) leukocytes. PFS was analyzed by MRD status at 3 months after treatment (EOT+3).RESULTSIbrutinib + venetoclax achieved deeper uMRD (<10-5) rates in bone marrow (BM) and peripheral blood (PB), respectively, in 40.6% and 43.4% of patients at EOT+3 versus 7.6% and 18.1% of patients receiving chlorambucil + obinutuzumab. Of these patients, uMRD (<10-5) in PB was sustained during the first year post-treatment (EOT+12) in 80.4% of patients receiving ibrutinib + venetoclax and 26.3% receiving chlorambucil + obinutuzumab. Patients with detectable MRD (dMRD; ≥10-4) in PB at EOT+3 were more likely to sustain MRD levels through EOT+12 with ibrutinib + venetoclax versus chlorambucil + obinutuzumab. PFS rates at EOT+12 were high among patients treated with ibrutinib + venetoclax regardless of MRD status at EOT+3: 96.3% and 93.3% in patients with uMRD (<10-4) and dMRD (≥10-4) in BM, respectively, versus 83.3% and 58.7% for patients receiving chlorambucil + obinutuzumab. PFS rates at EOT+12 also remained high in patients with unmutated immunoglobulin heavy-chain variable region (IGHV) receiving ibrutinib + venetoclax, independent of MRD status in BM.CONCLUSIONMolecular and clinical relapses were less frequent during the first year post-treatment with ibrutinib + venetoclax versus chlorambucil + obinutuzumab regardless of MRD status at EOT+3 and IGHV status. Even for patients not achieving uMRD (<10-4), PFS rates remained high with ibrutinib + venetoclax; this is a novel finding and requires additional follow-up to confirm its persistence over time